• Axsome Therapeutics has recently dosed the first patient in its FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled trial of solriamfetol in adolescents aged 12 to under 18 years with ADHD, assessing six-week changes in ADHD-RS-5 total scores across approximately 468 participants.
• This study extends solriamfetol’s development beyond sleep-related conditions into adolescent ADHD, underlining Axsome’s push to broaden its CNS treatment footprint across multiple indications.
• We’ll now examine how the initiation of this Phase 3 adolescent ADHD program for solriamfetol may reshape Axsome’s broader investment narrative.

Find 45 companies with promising cash flow potential yet trading below their fair value.

Axsome Therapeutics Investment Narrative Recap

To own Axsome Therapeutics, you generally need to believe its expanding CNS portfolio can offset current reliance on Auvelity, Sunosi and rising SG&A, while late stage assets convert into durable revenue. The FOCUS 3 Phase 3 start in adolescent ADHD incrementally supports that diversification theme but does not materially change the near term focus on execution for Auvelity, SYMBRAVO and pending late stage readouts, nor the key risk around ongoing net losses and a finite cash runway.

The recent settlement of all remaining SUNOSI patent litigation, with licensed generic entry pushed out to 2040, is particularly relevant here. It helps clarify the longer term economic window for solriamfetol across current and potential future indications, including ADHD, and reduces legal overhang. That visibility may matter for how investors weigh the costs of running multiple solriamfetol trials against the prospect of preserving exclusivity on any future incremental revenue.

Yet even with these clinical advances, investors should be aware that Axsome’s persistent net losses and cash runway constraints could still...

Axsome Therapeutics' narrative projects $2.5 billion revenue and $981.8 million earnings by 2029.

Uncover how Axsome Therapeutics' forecasts yield a $276.47 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most bearish analysts were already assuming Axsome must grow revenue to about US$1.5 billion and earnings to roughly US$433 million by 2029, so the FOCUS 3 ADHD trial could either help validate that growth path or make those assumptions look stretched, depending on how you see the added cost and risk of yet another late stage program.

Explore 8 other fair value estimates on Axsome Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Axsome Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 50 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.